Top 5 Drug Type | Count |
---|---|
Small molecule drug | 14 |
Diagnostic radiopharmaceuticals | 2 |
Radionuclide Drug Conjugates (RDC) | 1 |
Mechanism D2 receptor antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Dopamine reuptake inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism 5-HT2A receptor agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date08 Jan 2014 |
Sponsor / Collaborator |
Start Date29 Feb 2012 |
Sponsor / Collaborator |
Start Date21 Feb 2012 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Pridopidine ( D2 receptor x σ1 receptor ) | Huntington Disease More | Phase 3 |
NS-2359 ( DAT x SERT ) | Cocaine-Related Disorders More | Phase 2 |
PNU-96391 ( 5-HT2A receptor x D2 receptor ) | Fatigue Syndrome, Chronic More | Phase 2 |
AN-721 ( GABRA2 x GABRA3 ) | Pain More | Phase 1 |
[11C]NS-6417 ( SERT ) | Diagnostic agents More | Preclinical |